The FDA approving a new non-opioid painkiller, meaning it does not carry the risk of addiction.

The FDA has approved Journavx, an oral medication for treating pain that doesn't target the brain like addictive opioids.

The drug, Journavx, from Vertex Pharmaceuticals, reduced pain after surgery in clinical trials. Experts hope it can lead to fewer opioid prescriptions.

When politicians subordinate scientific institutions to electoral interests, they undermine immediate public health efforts ...

All the experts say socializing, ideally while doing that intellectual activity, can help a lot, because it not only stimulates the brain, but keeps us from feeling lonely. Loneliness often leads to ...

By Sarah Ladd Kentucky Lantern The American Lung Association gave Kentucky mostly failing grades when it comes to preventing tobacco use — and helping people access recovery — in a 2025 report ...

Readers and medical professionals discuss the Trump administration halting communication and travel at HHS. Regarding the Jan ...

The problem ingredient identified was "undeclared milk," which poses a risk to those with severe sensitivities or allergies.

Plus: President Donald Trump's comments over DEI in the aftermath of the tragedy. | Senate confirmation hearings continued ...

A nasal spray that contains esketamine — a potent derivative of ketamine — can now be taken on its own to treat adults with severe depression, the FDA says. Here's what that means.

The Prices and Consumer Affairs Division advises consumers of an ongoing recall of Lay's classic potato chips over undeclared ...